Side Effects of Methylphenidate and Desipramine Alone and in Combination in Children

Pataki, Caroly; Carlson, Gabrielle A.; Kelly, Kevin; Rapport, Mark D.; Biancaniello, Thomas M.

doi:10.1097/00004583-199309000-00028

Cited by 75 publications

(44 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our data add to a small literature on combined pharmacotherapy (Pataki 1993;Wilens et al 1995;Wilens et al 2008). The limited controlled data on combined regimens shown useful for ADHD include stimulants and tricyclic antidepressants (Pataki et al 1993), ATMX (Carlson et al 2007), or alpha agonists (Kurlan 2002;Hazell et al 2003;Palumbo et al 2008).…”

Section: Figmentioning

confidence: 76%

“…In four of these controlled studies, the combinations resulted in improvements in ADHD over those with stimulants alone. Moreover, in addition to improved co-morbid conditions (e.g., tics), improved cognition and complex problem solving were reported (Pataki et al 1993;Kurlan 2002). …”

Section: Figmentioning

confidence: 99%

“…The limited controlled data on combined regimens shown useful for ADHD include stimulants and tricyclic antidepressants (Pataki et al 1993), ATMX (Carlson et al 2007), or alpha agonists (Kurlan 2002;Hazell et al 2003;Palumbo et al 2008). In four of these controlled studies, the combinations resulted in improvements in ADHD over those with stimulants alone.…”

Section: Figmentioning

confidence: 99%

See 2 more Smart Citations

An Open Study of Adjunct OROS-Methylphenidate in Children and Adolescents Who Are Atomoxetine Partial Responders: I. Effectiveness

Wilens

Hammerness

Utzinger

et al. 2009

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

Objective: This study evaluated the effectiveness of adding OROS methylphenidate (MPH) to children who are partial responders to atomoxetine (ATMX) in the treatment of attention-deficit=hyperactivity disorder (ADHD). Methods: This is a two-phase, 7-week, open study in children aged 6-17 years. Phase I initiated ATMX for a minimum of 4 weeks. Phase II entered partial responders to ATMX and added up to 54 mg of OROS MPH to their regimen. Subjects were assessed on multiple outcomes, including ADHD, executive functioning, and adverse effects. All analyses were intent to treat, with last observation carried forward. Results: Fifty subjects who were partial responders to ATMX were treated with the combination therapy, with 41 subjects completing the entire protocol. There was a 40% reduction in their ADHD Rating Scale from the start of phase II through the end of study (from 21.14 AE 9.9 to 12.8 AE 9.7, t ¼ 6.5, p < 0.0001). In addition, there was a clinically significant reduction in the Clinical Global Index of ADHD severity from moderate to mild ADHD (start of phase II, 3.7; end of phase II, 2.7, 27%, t ¼ 6.5, p < 0.0001), as well as improvements in executive functioning. Conclusion: These results suggest that OROS MPH added to the regimen of partial responders to ATMX improves ADHD and executive functioning, necessitating further controlled trials.

show abstract

Section: Figmentioning

confidence: 76%

Section: Figmentioning

confidence: 99%

Section: Figmentioning

confidence: 99%

See 1 more Smart Citation

An Open Study of Adjunct OROS-Methylphenidate in Children and Adolescents Who Are Atomoxetine Partial Responders: I. Effectiveness

Wilens

Hammerness

Utzinger

et al. 2009

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Literatürde, metilfenidatın yan etkilerinden biri olarak kserostomi belirtilmiştir (28). Bazı araştırıcılar metilfenidatın subjektif olarak ağız kuruluğuna neden olduğunu belirtirken (29,30), bazıları tükürük akış hızı üzerinde herhangi bir etkisini saptamamıştır (31). İngiltere'de 2011 yılında yapılan bir çalışmada ise metilfenidat tedavisi gören çocukların ebeveynleri, ilacın yan etkisi olarak en sık (%34,3) iştah azalmasından şikayet etmişlerdir (32).…”

Section: Dikkat Eksikliği Ve Hiperaktivite Bozukluğu Tedavisinde Kullunclassified

“…DEHB'li çocukların sağlıklı çocuklarla karşılaştırıldığı bir çalışmada tırnak yeme ve bruksizm gibi kötü oral alışkanlıkların DEHB grubunda daha yaygın olduğu bildirilmiştir (71). DEHB'li çocuklarda bruksizmin, stimülan ilaçların yan etkisi olarak da ortaya çıkabileceği unutulmamalıdır (29,72).…”

Section: Dikkat Eksikliği Ve Hiperaktivite Bozukluğu Ve Parafonksiyonunclassified

Oral and Dental Health Problems of Children with Attention Deficit/Hyperactivity Disorders, and Solution Proposals

Yetiş¹,

Kırzıoğlu²

2017

jpr

View full text Add to dashboard Cite

GirişDikkat eksikliği ve hiperaktivite bozukluğu (DEHB), Amerikan Psikiyatri Derneği tarafından; çocukluk çağında, yaşa uygun olmayan seviyede dikkatsizlik, hiperaktivitedürtüsellik veya bunların kombinasyonu şeklinde kendini gösteren psikiyatrik bir bozukluk olarak tanımlanmaktadır (1).Çocuk ve ergenlerin yaklaşık %5-10'unu etkileyen, en yaygın görülen çocukluk çağı-başlangıçlı davranış bozukluğu (2) olan DEHB'nin, ülkemizde ve dünyada çocuk ve ergen psikiyatrisi polikliniklerine başvuran hastalarda en sık konulan tanılar arasında yer aldığı bildirilmektedir (3-5). Erkeklerde kızlara göre 8 kat daha fazla görülmekte olup (6), erkeklerde 6-9 yaş aralığında, kızlarda ise ergenlik döneminde prevalansının en yüksek seviyeye ulaştığı bildirilmiştir (7). ÖzABS TRACT Dikkat eksikliği ve hiperaktivite bozukluğu (DEHB), yaşa uygun olmayan seviyede dikkatsizlik, hiperaktivite-dürtüsellik veya bunların kombinasyonu şeklinde kendini gösteren en yaygın görülen çocukluk çağı-başlangıçlı davranış bozukluğudur. DEHB etiyolojisinde genetik ve çevresel faktörlerin rolü bulunmaktadır. Hastalığın kendisinden kaynaklı davranışsal problemler ve ilaç yan etkileri nedeniyle eklenen sorunlar, DEHB'li çocukların ağız ve diş sağlığı açısından risk grubunda yer almasına ve çocuk diş hekimliğinde özel ilgi gereksinimi olan hasta grubuna dahil olmalarına neden olmaktadır. Tedavisinde kullanılan ilaçların ağız kuruluğuna neden olabildiği belirtilmiştir. DEHB olan çocukların düşük oral hijyen alışkanlıkları ve yüksek diş çürüğü prevalansına sahip oldukları bildirilmiştir. Ayrıca bruksizm gibi parafonksiyonel alışkanlıklar ve dental travmalar da bu çocuklarda daha sık gözlenmektedir. Bu derlemede DEHB görülen çocuklarda ağız diş sağlığı ve davranış yönlendirme sorunlarından bahsedilmekte ve çözüm önerilerinde bulunulmaktadır. Anahtar Kelimeler: Dikkat eksikliği, hiperaktivite, diş sağlığı Attention deficit and hyperactivity disorder (ADHD) is the most common childhood onset behavioral disorder characterized by a developmentally inappropriate attention deficit, hyperactivity-impulsivity or a combination of these. Genetic and environmental factors play a role in the etiology. Because of the behavioral problems sourced from the disease itself and side effects of the drugs used in therapy, children with ADHD take place in the risk group in terms of oral and dental health problems and they are included in the group of patients who need special attention in pediatric dentistry. Drugs used in the treatment are known to cause dry mouth. Children with ADHD have been reported to have low oral hygiene habits and a high prevalence of dental caries. Also, parafunctional habits such as bruxism and dental trauma are observed more frequently in these children. In this review, oral health and behavior management problems in children with ADHD are pointed out, and solutions are suggested.

show abstract

Parent reports of sleep disturbances in stimulant-medicated children with attention-deficit hyperactivity disorder

Day

Abmayr

1998

J. Clin. Psychol.

View full text Add to dashboard Cite

In a study of the severity of sleep disturbances in children with attention-deficit hyperactivity disorder (ADHD) who are taking stimulant medication, parents of 20 children diagnosed as having ADHD and on medication, 20 unmedicated children with some other psychiatric diagnosis (OPD), and 20 nonclinical control children responded to a 40-question structured interview to report the frequency of their children's sleep disturbances occurring during a 1-month interval. Parents of children in the ADHD group reported significantly more problems than parents of children in the other groups on variables within all three categories of behaviors: (a) settling and going to sleep, (b) disruptions during sleep, and (c) morning activities. From 25% to 50% of these parents reported very frequent difficulties in their children settling and going to sleep. These findings indicate that monitoring sleep-related behaviors and providing adjunctive therapies for sleep-related disturbances would be beneficial for many families with ADHD children who are taking stimulant medication.

show abstract

Side Effects of Methylphenidate and Desipramine Alone and in Combination in Children

Cited by 75 publications

References 41 publications

An Open Study of Adjunct OROS-Methylphenidate in Children and Adolescents Who Are Atomoxetine Partial Responders: I. Effectiveness

An Open Study of Adjunct OROS-Methylphenidate in Children and Adolescents Who Are Atomoxetine Partial Responders: I. Effectiveness

Oral and Dental Health Problems of Children with Attention Deficit/Hyperactivity Disorders, and Solution Proposals

Parent reports of sleep disturbances in stimulant-medicated children with attention-deficit hyperactivity disorder

Contact Info

Product

Resources

About